Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $26.2100 (8.89%) ($26.2100 - $26.2100) on Mon. Aug. 23, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.31% (three month average) | RSI | 51 | Latest Price | $26.2100(8.89%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 3.5% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) IBB(61%) IWO(61%) ARKK(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.155% in a week (0% probabilities). VIXM(-46%) VXX(-40%) UUP(-20%) IGOV(-8%) UNG(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.155% (StdDev 4.31%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $23.32(12.39%) | 10 Day Moving Average | $22.91(14.4%) | 20 Day Moving Average | $25.69(2.02%) | To recent high | -35.2% | To recent low | 20.9% | Market Cap | $3.319b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |